Chronic Disease Management

Global Chronic Disease Management Market to Reach US$11.7 Billion by 2030

The global market for Chronic Disease Management estimated at US$5.5 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cardiovascular Diseases Management, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Diabetes Management segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 18.1% CAGR

The Chronic Disease Management market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 18.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Chronic Disease Management Market – Key Trends & Drivers Summarized

Why Is Chronic Disease Management Becoming Central to Global Healthcare Sustainability?
Chronic diseases—including cardiovascular disorders, diabetes, cancer, respiratory illnesses, and neurodegenerative conditions—account for the majority of global morbidity, mortality, and healthcare expenditure. As aging populations grow and lifestyle-related risk factors proliferate, health systems worldwide are shifting from episodic, acute care to continuous, preventive, and outcomes-based models of care. Chronic Disease Management (CDM) programs are emerging as essential frameworks to coordinate long-term patient monitoring, reduce hospital readmissions, and enhance quality of life for individuals with lifelong health conditions.

These models emphasize proactive risk stratification, patient education, care team collaboration, and use of real-time data to manage disease progression outside of traditional clinical settings. By focusing on early intervention, self-management, and continuity of care, CDM reduces total cost of care and eases the burden on overextended healthcare infrastructure. Governments and payers are increasingly incentivizing CDM adoption as part of value-based healthcare reforms aimed at improving outcomes per dollar spent.

How Are Digital Health Technologies and Remote Monitoring Tools Transforming Chronic Disease Care Pathways?
The integration of digital health technologies is revolutionizing how chronic conditions are managed, monitored, and measured. Remote patient monitoring (RPM) devices, wearable sensors, AI-powered mobile apps, and cloud-based platforms enable continuous collection and transmission of vital health metrics such as blood glucose, blood pressure, heart rate, and pulmonary function. These tools allow clinicians to track patient progress in real-time, detect anomalies early, and personalize treatment plans without requiring in-person visits.

Telemedicine, e-prescriptions, and automated alerts enhance the frequency and quality of patient-provider interactions, helping address medication adherence, lifestyle management, and care coordination. Machine learning algorithms applied to longitudinal health data are also improving predictive analytics, enabling earlier identification of high-risk patients and intervention triggers. As a result, technology-enabled CDM is supporting decentralized, data-driven care delivery models that are scalable, cost-efficient, and better aligned with patient expectations for accessibility and convenience.

Which Stakeholders Are Driving the Adoption of Chronic Disease Management Solutions Across Markets?
Payers and insurers are at the forefront of CDM adoption, recognizing its potential to reduce preventable hospitalizations, emergency care episodes, and redundant testing. By incentivizing providers through bundled payments, capitation models, and chronic care reimbursements, these stakeholders are embedding CDM into the economic foundation of healthcare delivery. Employers are also adopting workplace wellness and disease management programs to control insurance premiums, reduce absenteeism, and boost employee productivity.

Hospitals, physician networks, and accountable care organizations (ACOs) are investing in integrated care models that embed CDM into electronic health records (EHRs), case management workflows, and discharge planning. Pharmaceutical companies are entering the space through value-added services and digital therapeutics designed to improve treatment adherence and outcomes. Governments in both developed and emerging markets are expanding chronic care infrastructure through public health campaigns, national digital health missions, and targeted funding initiatives that position CDM as a public health imperative.

What Regulatory, Reimbursement, and Equity Challenges Could Impact the Future of Chronic Disease Management?
While the market outlook is promising, widespread CDM implementation faces structural and regulatory barriers. Fragmented reimbursement models, limited data interoperability, and inconsistent digital health regulations hinder the seamless coordination of care. In many healthcare systems, providers remain undercompensated for non-acute, time-intensive services central to CDM, including patient counseling, remote consultations, and care planning. Standardizing outcome metrics and incentivizing cross-specialty collaboration remain ongoing challenges.

Additionally, digital access disparities threaten to exacerbate health inequities, especially among low-income, rural, and elderly populations who are most in need of chronic care but least equipped to engage with digital tools. Ensuring inclusivity in platform design, data privacy compliance, and patient engagement strategies is critical. Stakeholders must also balance clinical oversight with technological automation to maintain safety, trust, and accountability. Without targeted policy reform, digital infrastructure investment, and workforce training, the potential of CDM to reduce healthcare inequities and costs may be limited.

Can Chronic Disease Management Deliver Scalable Impact Amid Growing Health System Pressures and Digital Transition?
As global healthcare systems face mounting financial strain, workforce shortages, and chronic disease prevalence, CDM stands at a strategic inflection point. The convergence of value-based care, digital innovation, and demographic necessity positions CDM as a core pillar of sustainable healthcare delivery. However, realizing this potential depends on aligning regulatory, economic, and technological frameworks to support continuous, equitable, and personalized care across geographies and care settings.

Sustained success will require robust cross-sector partnerships, reimbursement reform, investment in digital literacy, and scalable integration of AI, analytics, and remote tools. The question ahead is clear: Can chronic disease management evolve rapidly and inclusively enough to meet rising patient demands—while delivering long-term system-wide savings, population health improvement, and universal access to quality care?

SCOPE OF STUDY:

The report analyzes the Chronic Disease Management market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Cardiovascular Diseases, Diabetes, Respiratory Diseases, Cancer, Chronic Kidney Disease, Other Disease Types); Service Type (Disease Management Programs, Remote Patient Monitoring, Telehealth Services, Other Service Types); Deployment (On-Premise, Web-based, Cloud); End-User (Hospitals, Specialty Clinics, Home Care Settings, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Altruista Health
• Biofourmis
• CareHarmony
• Cedar Gate Technologies
• Cognizant
• Cosán Group
• Epic Systems Corporation
• Health Catalyst
• Infosys Limited
• MINES and Associates
• NXGN Management (NextGen Healthcare)
• Pegasystems Inc.
• Philips Healthcare
• ScienceSoft USA Corporation
• Siemens Healthineers
• TriZetto Corporation
• Veradigm Inc. (formerly Allscripts)
• Vida Health
• WellSky Corporation
• ZeOmega

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.